Skip to main content
Fig. 1 | Biology Direct

Fig. 1

From: RNF19A inhibits bladder cancer progression by regulating ILK ubiquitination and inactivating the AKT/mTOR signalling pathway

Fig. 1

RNF19A was expressed at low levels in BCa tissues and cell lines and was positively correlated with the clinical outcomes of patients with BCa. (A) RNF19A mRNA expression was analysed in various cancers using the TIMER database. (B) The RNF19A mRNA level was compared in normal and BCa tissues using the UALCAN database. (C) RNF19A mRNA expression in BCa with different lymphatic metastasis statuses, as determined from the UALCAN database. (D) qRT‒PCR analysis of RNF19A mRNA levels in normal and BCa tissues. (E-F) western blot analysis of RNF19A protein levels in normal and BCa tissues and quantitative analysis. (G) IHC analysis of RNF19A expression in normal and BCa tissues. Scale bar, 200 μm. (H-I) RNF19A mRNA and protein levels were detected in BCa cell lines (UM-UC-3, J82, SW780, T24, and 5637) and immortal ureteral epithelial cells (SV-HUC-1). (J) Kaplan‒Meier analysis of the correlation between overall survival and RNF19A expression levels. *P < 0.05, **P < 0.01, and ***P < 0.001

Back to article page

Biology Direct

ISSN: 1745-6150

Contact us